undamentalytics Newsletter
Sign in

Addex Therapeutics Ltd. revenue

Addex Therapeutics Ltd.'s revenue was $36,178 in fiscal 2025, down 92.1% on the year before. Since fiscal 2018 ($6.2m) it has grown at a compound -52.0% a year.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue6,1802,7813,8523,1901,4911,79645936
Growth on the year before—−55.0%+38.5%−17.2%−53.3%+20.5%−74.4%−92.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Addex Therapeutics Ltd. $36,178 -92.1% —
Lyell Immunopharma, Inc. $27,000 -55.0% -91.8%
AIM Immunotech Inc. $95,000 -21.5% -17.3%
Ibio, Inc. $100,000 -75.0% -62.4%
Lisata Therapeutics, Inc. $100,000 -90.7% —
Celldex Therapeutics, Inc. $158,000 -97.3% -63.5%

Compare with peers

Head to head: ADXN vs LYELADXN vs AIMADXN vs IBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Addex Therapeutics Ltd.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Addex Therapeutics Ltd.